Dose recommendations for gentamicin in the real-world obese population with varying body weight and renal (dys)function

Cornelis Smit 1,2, Anne M. van Schip3,4,5, Eric P. A. van Dongen6, Roger J. M. Brüggemann7, Matthijs L. Becker3,4 and Catherijne A. J. Knibbe1,2*

1Department of Clinical Pharmacy, St Antonius Hospital, Koekoekslaan 1, 3435 CM Nieuwegein, The Netherlands; 2Department of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands; 3Pharmacy Foundation of Haarlem Hospitals, Boerhaavelaan 24, 2035 RC Haarlem, The Netherlands; 4Department of Hospital Pharmacy, Spaarne Gasthuis, Boerhaavelaan 22, 2035 RC Haarlem, The Netherlands; 5Faculty of Science and Engineering, Antonius Deusinglaan 1, 9713 AV, University of Groningen, Groningen, The Netherlands; 6Department of Anesthesiology, St Antonius Hospital, Koekoekslaan 1, 3435 CM Nieuwegein, The Netherlands; 7Department of Pharmacy, Radboud Institute for Health Sciences, Radboudumc, Geert Grooteplein Zuid 8, 6525 GA Nijmegen, The Netherlands

*Corresponding author. E-mail: c.knibbe@antoniusziekenhuis.nl
Received 31 January 2020; accepted 15 June 2020

Background: The impact of weight on pharmacokinetics of gentamicin was recently elucidated for (morbidly) obese individuals with normal renal function.

Objectives: To characterize the pharmacokinetics of gentamicin in real-world obese patients, ultimately to develop dose recommendations applicable across the entire obese population.

Methods: In two large Dutch hospitals, all admitted patients with BMI ≥25 kg/m² with at least one gentamicin administration, at least one gentamicin and at least one creatinine serum concentration measurement were included. Data from one hospital, obtained from electronic health records, combined with prospective data of non-obese and morbidly obese people with normal renal function, served as the training dataset, and data from the second hospital served as the external validation dataset.

Results: In the training dataset (1187 observations from 542 individuals, total body weight (TBW) 52–221 kg and renal function (CKD-EPI) 5.1–141.7 mL/min/1.73 m²), TBW was identified as a covariate on distribution volume, and de-indexed CKD-EPI and ICU stay on clearance (all P < 0.001). Clearance was 3.53 L/h and decreased by 0.48 L/h with each 10 mL/min reduction in de-indexed CKD-EPI. The results were confirmed in the external validation (321 observations from 208 individuals, TBW 69–180 kg, CKD-EPI 5.3–130.0 mL/min/1.73 m²).

Conclusions: Based on the study, we propose specific mg/kg dose reductions with decreasing CKD-EPI values for the obese population, and extension of the dosing interval beyond 24 h when CKD-EPI drops below 50 mL/min/1.73 m². In ICU patients, a 25% dose reduction could be considered. These guidelines can be used to guide safe and effective dosing of gentamicin across the real-world obese population.

Introduction

Gentamicin is an aminoglycoside antibiotic that is commonly used for severe Gram-negative bloodstream infections. Both efficacy and toxicity closely correlate with serum concentrations, with the AUC0−24 relative to the MIC being paramount for its efficacy, as has been extensively reviewed in several papers in recent years.1–5 To ensure adequate exposure, current guidelines recommend a once-daily dose of 6–7 mg/kg for lean subjects with a normal renal function.4,6 Dose interval extension is recommended with renal impairment, since trough concentrations over 1 mg/L have been shown to be associated with nephrotoxicity and ototoxicity in clinical practice.7,8 Recently, we have characterized the influence of (morbid) obesity on the pharmacokinetics of gentamicin, based on a prospective full pharmacokinetic study in healthy non-obese and (morbidly) obese individuals with normal renal function.9 In that study we found that in this population of individuals without renal impairment, but with body weights up to 221 kg, gentamicin clearance could be predicted using total body weight (TBW) with an allometric exponent of 0.72.9 Since both renal function and...
Dosing gentamicin in real-world obese patients

(critical) illness are known to influence gentamicin clearance, it is likely that an adaptation of this dose nomogram is required for real-world obese patients with various degrees of renal function. This study aimed to characterize the pharmacokinetics of gentamicin in this real-world obese population, and ultimately to extend the dose nomogram for use in obese (critically) ill patients with and without renal impairment.

Patients and methods

Data

Data for this study were collected in two large Dutch teaching hospitals (St Antonius Hospital in Nieuwegein/Utrecht and the Spaarne Gasthuis in Haarlem). Over the period of October 2017 to April 2019, all patients with a BMI ≥25 mg/m² treated with gentamicin in the St Antonius Hospital were considered for inclusion. In this cohort, peak, trough and/or mid-way concentrations were measured as standard of care as specified by the gentamicin therapeutic drug monitoring (TDM) guideline from the Dutch Association of Hospital Pharmacists, which stipulates that gentamicin treatment courses should be individualized using gentamicin serum concentration measurements. Patient characteristics, gentamicin administration data and gentamicin concentrations were extracted from the electronic health record system. Patients were included in the analysis if they received at least one gentamicin administration and had at least one gentamicin and creatinine serum concentration measured during the course of therapy, without restrictions regarding gentamicin dose or time of sampling relative to the administration. Gentamicin was dosed at the discretion of the treating physician and usually varied between 5 and 3 mg/kg. Double entry of a single patient was allowed on condition that the time between the two gentamicin dosages was more than 14 days. Exclusion criteria were a gentamicin measurement without recorded gentamicin administration, a documented course of extracorporeal renal replacement therapy, or absence of a body weight measurement within 6 months of the first gentamicin administration. These data were analysed in conjunction with data from a previously performed rich-sampling prospective pharmacokinetic study (the AMIGO trial); these data were obtained upon a single first gentamicin administration. These data were analysed in conjunction with sampling relative to the administration. Gentamicin was dosed at the discretion of the treating physician and usually varied between 5 and 3 mg/kg. Double entry of a single patient was allowed on condition that the time between the two gentamicin dosages was more than 14 days. Exclusion criteria were a gentamicin measurement without recorded gentamicin administration, a documented course of extracorporeal renal replacement therapy, or absence of a body weight measurement within 6 months of the first gentamicin administration. These data were analysed in conjunction with data from a previously performed rich-sampling prospective pharmacokinetic study (the AMIGO trial); these data were obtained upon a single first gentamicin administration. These data were analysed in conjunction with sampling relative to the administration. Gentamicin was dosed at the discretion of the treating physician and usually varied between 5 and 3 mg/kg. Double entry of a single patient was allowed on condition that the time between the two gentamicin dosages was more than 14 days. Exclusion criteria were a gentamicin measurement without recorded gentamicin administration, a documented course of extracorporeal renal replacement therapy, or absence of a body weight measurement within 6 months of the first gentamicin administration. These data were analysed in conjunction with data from a previously performed rich-sampling prospective pharmacokinetic study (the AMIGO trial); these data were obtained upon a single first gentamicin administration.

Dose simulations

Using the final pharmacokinetic model, a single intravenous dose of gentamicin (given over 30 min) with different dose strategies was simulated in virtual subjects (n = 10000 per dose regimen) with randomly assigned values of MDRD, TBW (both with the same ranges as the training dataset) and gender. Height was imputed as 180 cm (for males) or 167 cm (for females), corresponding to the median values in the training dataset. For ABW-based dose strategies, realistic combinations of weight, height and gender were necessary to obtain realistic ABW values. To this end, values for these parameters were obtained by resampling combinations from the NHANES database (data from 1999 to 2016), where we stratified on TBW to ensure sufficient virtual subjects in each TBW stratum. MDRD-EPI values were de-indexed as done in the original training dataset by multiplying by BSA/1.73. With inclusion of IV, AUCon24 values were obtained for each subject using the SDES block in ADVAN6. As target for selecting the optimal dose strategy, we used the median AUCon24 from a reference subset of lean (non-ICU) subjects with a TBW <100 kg and CKD-EPI >60 ml/min/1.73 m² receiving 6 mg/kg TBW. This dose corresponds to the standard dose as currently recommended by the EUCAST. Exposure within 80%–125% of the target AUCon24 was considered equivalent, in line with the EMA guideline for bio-equivalence studies.

Results

A total of 1187 gentamicin concentrations from 542 individuals and 321 concentrations from 208 individuals were available in the training and validation dataset, respectively (Figure S1). Median body weight was 90.0 kg (range 53–221 kg) in the training dataset and 100 kg (range 69–180 kg) in the validation dataset. Renal function assessed by CKD-EPI ranged from 5.1 to 141.7 mL/min/1.73 m² (training dataset) and from 5.3 to 141.7 mL/min/1.73 m² (training dataset).
130.0 mL/min/1.73 m² (validation dataset). The baseline characteristics are shown in Table 1.

### Pharmacokinetic analysis

A two-compartment model best described the data with both weight and renal function as important covariates for gentamicin clearance. Figure 1a shows how clearance was found to change with both indexed (mL/min/1.73 m², left panel) and de-indexed CKD-EPI (mL/min, right panel). De-indexed CKD-EPI proved to be the most significant covariate, since inclusion of de-indexed CKD-EPI gave a larger OFV drop compared with the original, indexed CKD-EPI ($#807.0$ versus $#775.3$, $P < 0.001$), confirming the difference in trends for both covariates in Figure 1a. When indexed CKD-EPI was combined with TBW ($#816.2$, $P > 0.001$), a similar GOF and OFV drop compared with de-indexed CKD-EPI alone could be obtained, confirming that both renal function and body weight influence gentamicin clearance in this population. Since these two factors are merged in de-indexed CKD-EPI as one covariate, the OFV difference was not significant and we found considerable parameter correlation and an increase in condition number when implementing both CKD-EPI and TBW, we chose to include de-indexed CKD-EPI in the final model as a covariate for simultaneously describing weight and renal function. Here, for each 10 mL/min drop in de-indexed CKD-EPI, gentamicin clearance decreases by 0.48 L/h (95% CI 0.44–0.51 L/h), where an individual with a de-indexed CKD-EPI of 74 mL/min has a gentamicin clearance of 3.53 L/h (95% CI 3.28–3.79 L/h). In addition, Figure 1b shows that clearance was lower in patients admitted to the ICU. After incorporation of ICU admission status as a binary covariate in the model with de-indexed CKD-EPI on clearance, clearance was found to be reduced by 24.9% (95% CI 12.9%–34.2%) during ICU admission (OFV drop of $#20.7$, $P < 0.001$). Lastly, TBW was identified as a covariate on central volume of distribution ($V_1$) (OFV $#41.8$, $P < 0.001$), using a power function with an estimated exponent of 0.91. Fixing this exponent to 1, representing a linear relationship, resulted in a similar model (OFV $#0.45$, $P > 0.05$) and was entered in the final model. Finally, due to some correlation between IIV on clearance and volume of distribution of the central compartment, we included this correlation in the model using an OMEGABLOCK, resulting in a further reduction in OFV of $#17.4$ points ($P < 0.001$) and some improvement in GOF (data not shown).

The pharmacokinetic parameters of the final model are shown in Table 2. Covariate inclusion in the initial structural model led to a reduction in IIV from 81.0% to 36.3% and from 38.9% to 32.4% for clearance and $V_1$, respectively. Diagnostics of the final model (pvcVPC and GOF split for renal function and ICU admission status) are shown in Figures S2A, S3 and S4. These plots illustrate that the final model described all data, irrespective of level of renal dysfunction and ICU admission status.

### Table 1. Baseline characteristics of the training and external validation dataset

| Parameter                                                                 | Training dataset | External validation dataset |
|---------------------------------------------------------------------------|------------------|----------------------------|
| Number of individuals                                                    | 542              | 208                        |
| Age (years)                                                              | 69.5 (19.0–94.0) | 70.8 (60.5–78.4)           |
| Males/Females (% male)                                                   | 347/195 (64)     | 114/94 (55)                |
| Patients admitted to ICU during gentamicin treatment, n (% of total)     | 70 (13)          | 35 (17)                    |
| Height (cm)                                                              | 175 (150–198)    | 172 (146–200)              |
| BMI (kg/m²)                                                              | 29.3 (18.2–65.1) | 33.2 (26.0–56.8)           |
| Total body weight (kg)                                                   | 90.0 (53.3–220.5)| 100 (68.6–180.4)           |
| Adjusted body weight (kg)                                                | 78.1 (50.4–135.4)| 80.4 (53.4–115.9)          |
| Lean body weight (kg)                                                   | 62.1 (36.7–98.5) | 62.9 (39.2–88.1)           |
| Body surface area (m²)                                                  | 2.1 (1.6–3.1)    | 2.2 (1.7–3.0)              |
| Serum creatinine (µmol/L)                                                | 96 (24–763)      | 90 (22–920)                |
| Indexed CKD-EPI (mL/min/1.73 m²)                                         | 63.1 (5.1–141.7) | 70.7 (5.3–130.0)           |
| De-indexed CKD-EPI (mL/min)                                              | 77.3 (6.0–215.6) | 90.2 (7.1–180.4)           |
| Indexed MDRD (mL/min/1.73 m²)                                            | 61.7 (5.8–320.1) | 72.1 (5.7–297.2)           |
| De-indexed MDRD (mL/min)                                                 | 75.0 (6.4–444.1) | 93.1 (8.3–376.3)           |
| Cockcroft–Gault with LBW (mL/min)                                       | 54.2 (5.6–246.2) | 60.9 (7.2–232.5)           |
| Cockcroft–Gault with TBW (mL/min)                                       | 77.3 (7.9–404.5) | 92.5 (11.3–380.3)          |
| Gentamicin dose, mg, median (IQR)                                        | 360 (280–440)    | 400 (300–460)              |
| Gentamicin dose, mg/kg, median (IQR)                                     | 4.3 (3.1–5.1)    | 3.9 (3.0–4.7)              |
| No. of samples                                                           | 1187             | 321                        |
| No. of samples per individual, median (IQR)                              | 1 (1–2)          | 1 (1–2)                    |
| Time after dose, h, median (IQR)                                         | 19.7 (8.9–25.0)  | 17.5 (11.0–23.0)           |
| No. of samples <LLOQ, n (%)                                              | 194 (16)         | 61 (19)                    |

Data are shown as median (range) unless otherwise specified.

De-indexed by multiplying the original CKD-EPI or MDRD by BSA/1.73.
For the external validation dataset, both GOF and pVPC plots of the final pharmacokinetic model (Figures S5 and S6) were without bias (MPE = 0.39 mg/L, 95% CI = 8.98 to 1.70 mg/L) but with some imprecision (rRMSE 76.6%). This imprecision seems to be predominantly driven by the high concentrations, since rRMSE fell to 46.3% when calculated for observations <5 mg/L.

Dose simulations

Table 3 shows a CKD-EPI-based dose regimen based on the final model, which was designed for obese individuals (TBW >100 kg) with varying renal (dys)function to obtain similar exposure as compared with lean individuals with a normal renal function receiving the standard dose of 6 mg/kg. This CKD-EPI dosing regimen uses both body weight (i.e. mg/kg dosing) and indexed CKD-EPI (mL/min/1.73 m²), with the latter being chosen because this measure is readily available in clinical practice. The proposed dose varies from 6 mg/kg for obese individuals with CKD-EPI >120 mL/min to 1.8 mg/kg for obese individuals with CKD-EPI <30 mL/min, with dosing intervals varying between 24 and 48 h, respectively (Table 3). Figure 2 shows that using this CKD-EPI-based...
dosing strategy in obese individuals with varying degrees of renal impairment, similar exposures with similar variability over the first 24 h after infusion are obtained compared with lean individuals without renal impairment receiving 6 mg/kg TBW, who had a median AUC$_{0–24}$ of 85.9 mg*h/L. Figure 2 also shows that TBW- and ABW-based dose regimens yield increasing exposure (above the 125% upper limit of the median AUC$_{0–24}$ in lean individuals) with decreasing CKD-EPI. Figure S7 shows AUC$_{0–24}$ versus body weight for the different dose strategies. The times to reach the target trough concentration (<1 mg/L) for different renal function subgroups when using the CKD-EPI-based dose regimen are shown in Figure S8.

**Discussion**

In this report we show that gentamicin clearance in obese individuals with and without renal impairment can be adequately predicted by renal function (CKD-EPI), total body weight and ICU admission. The first two covariates can be combined by de-indexing CKD-EPI, where CKD-EPI (in mL/min/1.73 m$^2$) is corrected for BSA to result in a de-indexed CKD-EPI in mL/min. Although some other studies have found renal function estimates to be (to some extent) predictive of gentamicin clearance in obese individuals, the dataset and methodology in the current study are unique with respect to the ability to precisely characterize the influence of both renal function and body weight simultaneously. This could be done by using a unique dataset of both rich, prospective data collected in a wide range of body weights between 53 and 220 kg with normal renal function, together with a large clinical dataset of obese individuals with a wide range in renal function (CKD-EPI 5.1–141.7 mL/min/1.73 m$^2$). The combination of the datasets in our study allowed for the first time the full characterization of the influence of varying degrees of renal dysfunction within varying classes of obesity. The influence of body weight
alone on gentamicin clearance in the obese population has been described before in several studies, including a recent prospective study by our group in healthy non-obese and morbidity obese individuals without renal impairment, the data from which were also used in the current study.

Regarding the identified increase in gentamicin clearance with obesity, we anticipate that this increase could be explained by either an increase in glomerular filtration or an increase in renal tubular transport. The first explanation remains controversial since, for example, cefazolin, a drug that is dependent on glomerular filtration, showed no increased clearance in obesity. Also, for ciprofloxacin, which is mainly cleared renally, no substantial increase in clearance was reported. In contrast, for other renally excreted drugs such as tobramycin and vancomycin, increased clearance values were observed with increasing body weights, albeit to varying extents and using varying covariate functions. Considering the second explanation, the organic cation transporter 2 (OCT2) has been shown to be increased in obese overfed mice and obese humans, and is associated with increased renal gentamicin tubular uptake. Consequently, we anticipate that the increase in gentamicin clearance with obesity may be related to the increase in OCT2 transporters in the kidneys of obese individuals. While this hypothesis supports the proposed use of mg/kg in our dosing strategy (Table 3), dose reductions are required in cases of reduced CKD-EPI renal function.

In addition to renal function and body weight, ICU stay proved to be an independent predictor for gentamicin clearance, regardless of renal function, with a reduction in CL of 13%–34% in cases where the patient was admitted to the ICU. Although most studies in critically ill patients found creatinine clearance to be predictive of gentamicin clearance, some studies found critical illness as an additional covariate for gentamicin clearance. A possible explanation for our finding might lie in the fact that serum creatinine is actually a late marker for renal impairment, necessitating ICU admission as a separate covariate in the model. Fortunately, novel biomarkers for acute renal function have emerged that might be better suited for estimating acute kidney failure in an earlier stage. Future research should focus on the performance of these biomarkers in predicting gentamicin clearance. Until then, we suggest considering a dose reduction of 25% relative to our CKD-EPI-based dose nomogram (Table 3) when the patient is admitted to the ICU and there is a clinical suspicion of developing renal failure that may not yet be reflected in serum creatinine.

The strengths of our study are the large dataset with both rich, prospectively collected data in obese and non-obese healthy volunteers with normal renal function and clinically collected TDM data in real-world obese patients. As depicted in Figure S1, sampling times were well distributed relative to the start of the gentamicin infusion (from 0 up to 48 h), maximizing our ability to characterize the full pharmacokinetic profile. Additionally, our data consisted of a wide range of covariates such as renal function and body weight, boosting the power to simultaneously characterize these covariates on gentamicin pharmacokinetics. Secondly, we substantiated the validity of our model and CKD-EPI-based dosing recommendation by validating the predictive performance of our pharmacokinetic model in an external independent clinical dataset.

In this study we present an easy-to-use CKD-EPI-based dose strategy for gentamicin that is applicable across the whole clinical population of obese patients with body weights up to 220 kg, both with and without renal impairment. Like the pharmacokinetic model, our dose recommendation incorporates both renal function (CKD-EPI) and body weight (mg/kg-based dosing), with a reduction in mg/kg dose depending on the CKD-EPI, and a 25% dose reduction to consider upon admittance to the ICU. Additionally, considering the time to reach a trough concentration below 1 mg/L (shown in Figure S8), extension of the dosing interval beyond 24 h seems necessary when CKD-EPI drops below 50 mL/min/1.73 m². Our proposed dose strategy targets exposure similar to that in lean individuals with normal renal function receiving 6 mg/kg, which is the dose recommended by EUCAST. Our AUC0–24/MIC target thresholds for aminoglycoside efficacy have been proposed over the years, although these are mainly based on preclinical (animal) infection models. Consequently, there is still a lack of data on the performance of these targets in clinical practice.

We therefore argue that, until more knowledge is available, we should try to optimize gentamicin treatment in obese individuals with and without renal failure by targeting exposures similar to those obtained in lean individuals receiving the currently recommended dose. Some hospitals may have other guidelines for dosing gentamicin in lean individuals, for example 5 or 7 mg/kg TBW. Our proposed dose strategy for obese individuals can, however, be easily adapted to target these exposures. For the reader’s convenience, we have provided such adapted dose recommendations in Table S3 in the Supplementary data.

Some limitations may apply to our study. First, patients on renal replacement therapy were excluded from our study, so our results cannot be extrapolated to this population. Second, there is still considerable variability in the obtained AUC0–24 when using our proposed dose nomogram. However, the magnitude of this variability is similar to what we observed in lean individuals with normal renal function receiving 6 mg/kg TBW. As is customary for the normal population, we strongly recommend individualizing the gentamicin dose using therapeutic drug monitoring in obese individuals as well.

In conclusion, based on a pharmacokinetic analysis of individuals with a large range in body weight and renal function, we propose a novel CKD-EPI-based dose strategy (Table 3) to be used in the whole clinical obese population. A dose reduction of 25% might be necessary in ICU patients. Using this dose strategy, an exposure can be obtained similar to that of lean subjects without renal impairment receiving 6 mg/kg TBW.

Funding
The AMIGO trial was funded by an institutional research grant number (ZonMW) 836041004.

Transparency declarations
R.J.M.B. declares that he has no conflicts of interest with regards to this work. Outside of this work, he has served as consultant to and has received unrestricted research grants from Astellas Pharma Inc., F2G, Amplyx, Gilead Sciences, Merck Sharpe and Dohme Corp., and Pfizer Inc. All payments were invoiced by the Radboud University Medical Centre. All other authors declare no conflicts of interest.
Author contributions
C.S., E.P.A.D., R.J.M.B. and C.A.J.K. designed the study, C.S., E.P.A.D., A.M.S. and M.L.B. collected the data, C.S., C.A.J.K. analysed the data, C.S., C.A.J.K. drafted the initial manuscript, all authors thoroughly revised the manuscript and all authors approved the final version of the manuscript.

Supplementary data
Tables S1 to S3 and Figures S1 to S8 are available as Supplementary data at JAC Online.

References
1 Drusano GL, Ambrose PG, Bhavnani SM et al. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis 2007; 45: 753–60.
2 Drusano GL, Louie A. Optimization of aminoglycoside therapy. Antimicrob Agents Chemother 2011; 55: 2528–31.
3 Pai MP, Russo A, Novelli A et al. Simplified equations using two concentrations to calculate area under the curve for aminoglycosids with concentration-dependent pharmacodynamics: daptomycin as a motivating example. Antimicrob Agents Chemother 2014; 58: 3162–7.
4 USCAST: The National Antimicrobial Susceptibility Testing Committee for the United States. Aminoglycoside In Vitro Susceptibility Test Interpretive Criteria Evaluations, version 1.3. 2019. http://www.uscast.org/documents.html.
5 Nielsen EI, Cars O, Friberg LE. Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PK/PD model: a step toward model-based dose optimization. Antimicrob Agents Chemother 2011; 55: 4619–30.
6 EUCAST. Clinical Breakpoints—Bacteria (v 10.0). 2020. https://eucast.org/clinical_breakpoints/.
7 Reeves DS, MacGowan AP. Once-daily aminoglycoside dosing. Lancet 1993; 341: 895–6.
8 Prins JM, Büller HR, Kuiper EJ et al. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993; 341: 335–9.
9 Smit C, Wasmann RE, Goulooze SC et al. A prospective clinical study characterizing the influence of morbid obesity on the pharmacokinetics of gentamicin: towards individualized dosing in obese patients. Clin Pharmacokinet 2019; 58: 1333–43.
10 Rea RS, Capitano B. Optimizing use of aminoglycosides in the critically ill. Semin Respir Crit Care Med 2007; 28: 596–603.
11 Coenradie S, Touw D. TDM Monografie: Gentamicine. https://tdm-mongrafie.org/monografie/gentamicine/.
12 Janmahasatian S, Duffull SB, Ash S et al. Quantification of lean bodyweight. Clin Pharmacokinet 2005; 44: 1051–65.
13 Beal SL, Sheiner LB, Boeckmann A. NONMEM User’s Guide. University of California, San Francisco, CA, 1999.
14 R Core Team. R: A Language and Environment for Statistical Computing, 2019.
15 Keizer RJ, Karlsson MO, Hooker A. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol 2013; 2: e50.
16 Lindbom L, Pihlgren P, Jonsson EN et al. PsN-Toolkit—a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 2005; 79: 241–57.
17 Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 2001; 28: 481–504.
18 Bauer LA, Edwards WAD, Dellinger EP et al. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol 1983; 24: 643–7.
19 Bergstrand M, Hooker AC, Wallin JE et al. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 2011; 13: 143–51.
20 Centers for Disease Control and Prevention (CDC). National Health and Nutrition Examination Survey Data (NHANES) 1999–2016.
21 Committee for Medicinal Products for Human Use (CHMP)-EMA. Guideline on the Investigation of Bioequivalence—CPMP/EWP/QWP/1401/98 Rev. 1. 2010.
22 Pai MP, Nafziger AN, Bertino JS. Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients. Antimicrob Agents Chemother 2011; 55: 4006–11.
23 Lim AKH, Mathanasenarajah G, Lamour I. Assessment of aminoglycoside dosing and estimated glomerular filtration rate in determining gentamicin and tobramycin area under the curve and clearance. Intern Med J 2015; 45: 319–29.
24 Traynor AM, Nafziger AN, Bertino JS. Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother 1995; 39: 545–8.
25 Leader WG, Tsuabki T, Chandler MH. Creatinine-clearance estimates for predicting gentamicin pharmacokinetic values in obese patients. Am J Hosp Pharm 1994; 51: 2125–30.
26 Schwartz SN, Pazin GJ, Lyon JA et al. A controlled investigation of the pharmacokinetics of gentamicin and tobramycin in obese subjects. J Infect Dis 1978; 138: 499–505.
27 Brill MJ, Houwink API, Schmidt S et al. Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis. J Antimicrob Chemother 2014; 69: 715–23.
28 Hollenstein UM, Brunner M, Schmid R et al. Soft tissue concentrations of ciprofloxacin in obese and lean subjects following weight-adjusted dosing. Int J Obes Relat Metab Disord 2001; 25: 354–8.
29 Smit C, Wasmann RE, Wiezer MJ et al. Tobramycin clearance is best described by renal function estimates in obese and non-obese individuals: results of a prospective rich sampling pharmacokinetic study. Pharm Res 2019; 36: 112.
30 Smit C, Wasmann RE, Goulooze SC et al. Population pharmacokinetics of vancomycin in obesity: finding the optimal dose for (morbidly) obese individuals. Br J Clin Pharmacol 2020; 86: 303–17.
31 Gai Z, Visentin M, Hiller C et al. Organic cation transporter 2 overexpression may confer an increased risk of gentamicin-induced nephrotoxicity. Antimicrob Agents Chemother 2016; 60: 5573–80.
32 Hodiamont CJ, Juffermans NP, Bauman CSC et al. Determinants of gentamicin concentrations in critically ill patients: a population pharmacokinetic analysis. Int J Antimicrob Agents 2017; 49: 204–11.
33 Roberts JA, Field J, Visser A et al. Using population pharmacokinetics to determine gentamicin dosing during extended daily dialysis in critically ill patients with acute kidney injury. Antimicrob Agents Chemother 2010; 54: 3635–40.
34 Gonçalves-Pereira J, Martins A, Pêvoa P. Pharmacokinetics of gentamicin in critically ill patients: pilot study evaluating the first dose. Clin Microbiol Infect 2010; 16: 1258–63.
35 Thall DA, Shikuma LR, Miller TQ et al. Physiologic response of stress and aminoglycoside clearance in critically ill patients. Crit Care Med 1993; 21: 248–51.
36 Teo SH, Endre ZH. Biomarkers in acute kidney injury (AKI). Best Pract Res Clin Anaesthesiol 2017; 31: 331–44.
37 Lee PI. Design and power of a population pharmacokinetic study. Pharm Res 2001; 18: 75–82.